Revolution Medicines (RVMD) Total Current Liabilities (2019 - 2026)

Revolution Medicines has reported Total Current Liabilities for 8 years, with the latest figure at $289.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 82.6% year-over-year to $289.6 million; the trailing twelve-month figure through Mar 2026 stood at $289.6 million (up 82.6% YoY), and the FY2025 full-year result was $290.4 million, up 77.18% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $289.6 million, roughly flat from $290.4 million in the prior quarter.
• The five-year high for Total Current Liabilities was $290.4 million in Q4 2025, with the low at $54.6 million in Q1 2023.
• Average Total Current Liabilities over 5 years is $133.0 million, with a median of $105.3 million recorded in 2024.
• Peak annual rise in Total Current Liabilities reached 132.08% in 2023, while the deepest fall reached 4.91% in 2023.
• Tracing RVMD's Total Current Liabilities over 5 years: stood at $62.0 million in 2022, then jumped by 132.08% to $143.9 million in 2023, then climbed by 13.95% to $163.9 million in 2024, then surged by 77.18% to $290.4 million in 2025, then declined by 0.28% to $289.6 million in 2026.
• The last three Total Current Liabilities figures came in at $289.6 million (Q1 2026), $290.4 million (Q4 2025), and $245.6 million (Q3 2025), per Business Quant data.

Peer Comparison